CARD proteins as therapeutic targets in cancer

被引:35
作者
Damiano, JS [1 ]
Reed, JC [1 ]
机构
[1] Burnham Inst, La Jolla, CA 92037 USA
关键词
caspase; interleukin-1; apoptosis; cancer; NF-kappa B; drug resistance;
D O I
10.2174/1389450043345470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteins containing a caspase-associated recruitment domain (CARD) have been established as key regulators of cell death and, more recently, cytokine production. During the last several years, the number of proteins identified within this family has grown immensely and many aspects of their function point to their potential utility as novel drug targets in the treatment of cancer. Several CARD family proteins are critical components of the conserved cell death machinery which, when dysregulated, promotes oncogenesis and contributes prominently to tumor resistance to chemotherapy. The pro-apoptotic protein Apaf1. which is inactivated in sonic cancers. is a CARD protein that is indispensable for mitochondria-induced apoptosis. Other antiapoptotic CARD proteins, such as TUCAN/CARDINAL/ CARD8. have been shown to protect tumours from cell death stimuli and to be over-expressed in certain forms of cancer. Therapeutics that activate or inhibit CARD proteins may therefore be potentially utilized as novel chemo-sensitizing agents When used in conjunction with conventional chemotherapy. Other CARD proteins influence cellular processes through the regulation of NF-kappaB or caspase-1, which governs the levels of interleukin-1beta (IL-1beta) addition to its pro-inflammatory properties, this cytokine also contributes to neoplastic progression by promoting angiogenesis. proliferation, and the metastasis of many tumors. Many of the IL-1beta -regulating CARD proteins also contain a nucleotide binding/oligomerization domain known as a NACHT and may therefore be amenable to targeting by small molecule compounds. This review examines the role of CARD proteins in cytoprotection and cytokine processing in file context of neoplasia and presents strategies for using this information in devising potential novel anticancer agents.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 97 条
[51]   Effects of methylation on expression of TMS1/ASC in human breast cancer cells [J].
Levine, JJ ;
Stimson-Crider, KM ;
Vertino, PM .
ONCOGENE, 2003, 22 (22) :3475-3488
[52]   MICE DEFICIENT IN IL-1-BETA-CONVERTING ENZYME ARE DEFECTIVE IN PRODUCTION OF MATURE IL-1-BETA AND RESISTANT TO ENDOTOXIC-SHOCK [J].
LI, P ;
ALLEN, H ;
BANERJEE, S ;
FRANKLIN, S ;
HERZOG, L ;
JOHNSTON, C ;
MCDOWELL, J ;
PASKIND, M ;
RODMAN, L ;
SALFELD, J ;
TOWNE, E ;
TRACEY, D ;
WARDWELL, S ;
WEI, FY ;
WONG, W ;
KAMEN, R ;
SESHADRI, T .
CELL, 1995, 80 (03) :401-411
[53]   T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphorna that expresses nuclear BCL10 [J].
Liu, HX ;
Ye, HT ;
Dogan, A ;
Ranaldi, R ;
Hamoudi, RA ;
Bearzi, T ;
Isaacson, PG ;
Du, MQ .
BLOOD, 2001, 98 (04) :1182-1187
[54]   The role of interleukin-1β in the pathogenesis of multiple myeloma [J].
Lust, JA ;
Donovan, KA .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) :1117-+
[55]  
Ma MH, 2003, CLIN CANCER RES, V9, P1136
[56]   BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression [J].
Maes, B ;
Demunter, A ;
Peeters, B ;
De Wolf-Peeters, C .
BLOOD, 2002, 99 (04) :1398-1404
[57]   The inflammasome:: A molecular platform triggering activation of inflammatory caspases and processing of proIL-β [J].
Martinon, F ;
Burns, K ;
Tschopp, J .
MOLECULAR CELL, 2002, 10 (02) :417-426
[58]  
Moriai R, 2002, ANTICANCER RES, V22, P4163
[59]   Direct activation of the apoptosis machinery as a mechanism to target cancer cells [J].
Nguyen, JT ;
Wells, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7533-7538
[60]  
Notarbartolo M, 2004, ONCOL REP, V11, P133